Jump to content
RemedySpot.com

Re: Gleevec Patients In Noncompliance

Rate this topic


Guest guest

Recommended Posts

Lottie:  Thank You for all the articles you post.  It surely  helps me, as I

am sure many others will agree.  When I started on my Gleevec back in 2000.  I

was told in no uncertain terms that 400mg. was your basic dose.  I know some

doctors have given lower doses, due to the patient complaining of the side

effects.  Some have complained of very severe symptoms from the Gleevec.  I

still suffer with side effects after 10 years.  A lot of people say they have

felt that the side effects have gotten better after long term use. Everyone is

different in how they react, or metabolize their drugs.  I never asked for a

lower dose, and my Oncologist never suggested me lowering it either.  I still

take 400mg. a day, and I just feel that if I did not take it as prescribed I

would not have gotten as far as I have.  I just pray that it keeps doing its

job for me, and if it should stop working then I guess I will have to try

another drug.  My fear has been

that I might not do as well with another drug as I have with the Gleevec.  I

am very compliant and Thank God Everyday that I got to PCRU, and that I will

continue to do well.

A

From: Lottie Duthu <lotajam@...>

Subject: [ ] Gleevec Patients In Noncompliance

" CML " < >

Date: Tuesday, October 12, 2010, 11:24 PM

 

I think this was a topic of conversation some months ago when we found that some

doctors were taking their patients off Gleevec for long periods of time. Here is

information on the adverse effects to the patient's responses and a very

cmpelling story for doctors or their patients who think they can get away with

it:

" About 25% of patients being treated with imatinib (Gleevec, Novartis) for

chronic myeloid leukemia (CML) did not take the drug as prescribed, and ended up

taking less than 90% of their imatinib doses. This had an adverse effect on

their cytogenic and molecular responses, and might ultimately affect long-term

outcomes, say researchers in the United Kingdom.

" A few details of the study were discussed by coauthor Lina Eliasson, a PhD

student at the School of Pharmacy, University of London, United Kingdom, at a

press briefing in London last week. The briefing focused on cancer-drug

development, the subject of this year's School of Pharmacy lecture.

" The extent of noncompliance seen with imatinib is similar to that seen in other

studies of chronic diseases, but it was rather " surprising " in this context of a

life-threatening disease, said Nick Barber, PhD, professor of practice and

policy at from the School of Pharmacy, an expert on compliance, and Ms.

Eliasson's PhD supervisor. This study is very important and serves as a warning

for other oral cancer drugs.

" You would think that cancer patients would be more motivated to keep taking

their drug, and so the finding is rather counterintuitive, " he said in an

interview with Medscape Oncology. But he also said that there are other studies

that suggest that noncompliance is a problem in other life-threatening

disorders, and mentioned a study that found that 17% of patients who had

received a kidney transplant were noncompliant with their immunosuppressive drug

therapy, even though not taking these drugs would reduce the likelihood of the

transplant surviving. " (Complete article cited below shows that none of the

patients who took less than 80% of the imatinib dose had a complete response in

which no leukemic cells remained.)

http://www.medscape.com/viewarticle/715040

___________________________

Dr. Janet Rowley: Pioneer of Cancer Genetics Still Bikes to Work at Age 85 Years

" Janet on Rowley, MD, whose pioneering research showed that genetic

mutations play a crucial role in cancer, has been awarded the Margaret L. Kripke

Legend Award by the University of Texas M.D. Cancer Center. The award

was bestowed in recognition of her efforts to mentor women and other minorities

as they pursue their scientific careers. " (Read rest of her bio)

http://www.medscape.com/viewarticle/726089

____________________

FYI,

Lottie Duthu

Link to comment
Share on other sites

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...